Stem definition | Drug id | CAS RN |
---|---|---|
tyrosine kinase inhibitors | 4190 | 941678-49-5 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 16, 2011 | FDA | INCYTE CORP |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Platelet count decreased | 392.83 | 18.58 | 297 | 14992 | 99727 | 46571046 |
Platelet count increased | 383.46 | 18.58 | 154 | 15135 | 14720 | 46656053 |
Haemoglobin decreased | 356.60 | 18.58 | 312 | 14977 | 128637 | 46542136 |
Splenomegaly | 352.67 | 18.58 | 129 | 15160 | 9559 | 46661214 |
Myelofibrosis | 244.34 | 18.58 | 61 | 15228 | 1198 | 46669575 |
Blood count abnormal | 236.67 | 18.58 | 116 | 15173 | 17762 | 46653011 |
Anaemia | 201.33 | 18.58 | 325 | 14964 | 255454 | 46415319 |
Weight increased | 178.15 | 18.58 | 243 | 15046 | 164230 | 46506543 |
Product dose omission issue | 157.37 | 18.58 | 232 | 15057 | 168288 | 46502485 |
Death | 154.52 | 18.58 | 339 | 14950 | 335209 | 46335564 |
Contusion | 153.14 | 18.58 | 165 | 15124 | 87322 | 46583451 |
White blood cell count increased | 148.60 | 18.58 | 120 | 15169 | 44099 | 46626674 |
Red blood cell count decreased | 112.69 | 18.58 | 90 | 15199 | 32533 | 46638240 |
Acute myeloid leukaemia | 97.33 | 18.58 | 62 | 15227 | 15716 | 46655057 |
Increased appetite | 85.73 | 18.58 | 46 | 15243 | 8481 | 46662292 |
Thrombocytopenia | 78.37 | 18.58 | 145 | 15144 | 126436 | 46544337 |
Primary myelofibrosis | 75.44 | 18.58 | 14 | 15275 | 58 | 46670715 |
Flatulence | 73.75 | 18.58 | 67 | 15222 | 28811 | 46641962 |
Dizziness | 64.84 | 18.58 | 251 | 15038 | 340163 | 46330610 |
Fatigue | 62.98 | 18.58 | 376 | 14913 | 608321 | 46062452 |
Drug hypersensitivity | 55.98 | 18.58 | 7 | 15282 | 243818 | 46426955 |
Night sweats | 50.41 | 18.58 | 53 | 15236 | 27197 | 46643576 |
Haematocrit decreased | 49.13 | 18.58 | 59 | 15230 | 34998 | 46635775 |
Febrile neutropenia | 47.13 | 18.58 | 99 | 15190 | 94528 | 46576245 |
Abdominal distension | 41.58 | 18.58 | 81 | 15208 | 73270 | 46597503 |
Bone pain | 39.96 | 18.58 | 62 | 15227 | 46828 | 46623945 |
Transfusion | 38.36 | 18.58 | 33 | 15256 | 13198 | 46657575 |
Drug ineffective | 38.08 | 18.58 | 106 | 15183 | 677732 | 45993041 |
Graft versus host disease in liver | 36.40 | 18.58 | 11 | 15278 | 447 | 46670326 |
Graft versus host disease | 35.99 | 18.58 | 24 | 15265 | 6564 | 46664209 |
Graft versus host disease in gastrointestinal tract | 35.07 | 18.58 | 17 | 15272 | 2533 | 46668240 |
Epistaxis | 34.02 | 18.58 | 69 | 15220 | 64236 | 46606537 |
Platelet count abnormal | 33.73 | 18.58 | 17 | 15272 | 2755 | 46668018 |
Therapeutic response unexpected | 33.67 | 18.58 | 33 | 15256 | 15583 | 46655190 |
Fungal endocarditis | 33.07 | 18.58 | 9 | 15280 | 250 | 46670523 |
Muscle spasms | 32.19 | 18.58 | 101 | 15188 | 123012 | 46547761 |
White blood cell count decreased | 32.08 | 18.58 | 95 | 15194 | 112136 | 46558637 |
Splenectomy | 31.94 | 18.58 | 10 | 15279 | 458 | 46670315 |
Eye infection bacterial | 29.50 | 18.58 | 7 | 15282 | 110 | 46670663 |
Spleen disorder | 28.79 | 18.58 | 11 | 15278 | 917 | 46669856 |
Infective aneurysm | 28.40 | 18.58 | 9 | 15280 | 429 | 46670344 |
Gout | 28.30 | 18.58 | 26 | 15263 | 11330 | 46659443 |
Product use in unapproved indication | 28.29 | 18.58 | 79 | 15210 | 90194 | 46580579 |
Leukaemia | 28.23 | 18.58 | 16 | 15273 | 3279 | 46667494 |
Iron overload | 27.16 | 18.58 | 10 | 15279 | 752 | 46670021 |
Bronchopulmonary aspergillosis | 26.54 | 18.58 | 21 | 15268 | 7475 | 46663298 |
Blast cell count increased | 25.84 | 18.58 | 8 | 15281 | 353 | 46670420 |
Toxicity to various agents | 25.83 | 18.58 | 19 | 15270 | 211747 | 46459026 |
Haemorrhage | 25.67 | 18.58 | 56 | 15233 | 54813 | 46615960 |
Headache | 24.75 | 18.58 | 252 | 15037 | 478100 | 46192673 |
Second primary malignancy | 24.51 | 18.58 | 19 | 15270 | 6565 | 46664208 |
Cytomegalovirus infection reactivation | 23.89 | 18.58 | 11 | 15278 | 1461 | 46669312 |
Pancytopenia | 23.35 | 18.58 | 71 | 15218 | 84987 | 46585786 |
Overdose | 23.20 | 18.58 | 3 | 15286 | 101976 | 46568797 |
Chronic graft versus host disease | 22.72 | 18.58 | 13 | 15276 | 2712 | 46668061 |
JC virus infection | 22.62 | 18.58 | 11 | 15278 | 1651 | 46669122 |
Drug interaction | 22.55 | 18.58 | 20 | 15269 | 203074 | 46467699 |
Herpes zoster | 21.86 | 18.58 | 60 | 15229 | 67812 | 46602961 |
Condition aggravated | 21.82 | 18.58 | 29 | 15260 | 245023 | 46425750 |
Adenocarcinoma metastatic | 21.67 | 18.58 | 5 | 15284 | 69 | 46670704 |
Blood lactate dehydrogenase increased | 21.64 | 18.58 | 30 | 15259 | 20470 | 46650303 |
Asthenia | 21.19 | 18.58 | 174 | 15115 | 310901 | 46359872 |
Acute leukaemia | 20.03 | 18.58 | 9 | 15280 | 1129 | 46669644 |
Leukocytosis | 20.01 | 18.58 | 31 | 15258 | 23367 | 46647406 |
Encopresis | 19.75 | 18.58 | 5 | 15284 | 104 | 46670669 |
Encephalitis fungal | 19.67 | 18.58 | 4 | 15285 | 29 | 46670744 |
Aspergillus infection | 19.59 | 18.58 | 17 | 15272 | 6873 | 46663900 |
Epstein-Barr virus infection reactivation | 19.48 | 18.58 | 6 | 15283 | 260 | 46670513 |
Red blood cell count increased | 19.03 | 18.58 | 11 | 15278 | 2339 | 46668434 |
Promyelocyte count increased | 19.00 | 18.58 | 3 | 15286 | 3 | 46670770 |
Graft versus host disease in skin | 18.96 | 18.58 | 11 | 15278 | 2356 | 46668417 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Myelofibrosis | 386.07 | 16.56 | 103 | 17117 | 1468 | 29933790 |
Splenomegaly | 385.33 | 16.56 | 177 | 17043 | 13303 | 29921955 |
Platelet count decreased | 330.15 | 16.56 | 353 | 16867 | 105776 | 29829482 |
Death | 246.64 | 16.56 | 594 | 16626 | 356689 | 29578569 |
Haemoglobin decreased | 224.82 | 16.56 | 301 | 16919 | 113797 | 29821461 |
Anaemia | 204.89 | 16.56 | 400 | 16820 | 207592 | 29727666 |
Platelet count increased | 186.55 | 16.56 | 94 | 17126 | 8648 | 29926610 |
White blood cell count increased | 161.51 | 16.56 | 153 | 17067 | 39520 | 29895738 |
Blood count abnormal | 153.32 | 16.56 | 91 | 17129 | 11561 | 29923697 |
Acute myeloid leukaemia | 141.95 | 16.56 | 102 | 17118 | 17904 | 29917354 |
Product dose omission issue | 126.91 | 16.56 | 205 | 17015 | 91426 | 29843832 |
Febrile neutropenia | 123.06 | 16.56 | 220 | 17000 | 106473 | 29828785 |
Second primary malignancy | 122.99 | 16.56 | 64 | 17156 | 6292 | 29928966 |
Contusion | 81.28 | 16.56 | 95 | 17125 | 31185 | 29904073 |
Red blood cell count decreased | 80.45 | 16.56 | 87 | 17133 | 26234 | 29909024 |
Fatigue | 68.93 | 16.56 | 364 | 16856 | 320309 | 29614949 |
Blast cell count increased | 65.03 | 16.56 | 24 | 17196 | 1025 | 29934233 |
Night sweats | 64.77 | 16.56 | 59 | 17161 | 14469 | 29920789 |
Iron overload | 60.37 | 16.56 | 24 | 17196 | 1257 | 29934001 |
Acute leukaemia | 59.52 | 16.56 | 23 | 17197 | 1116 | 29934142 |
Toxicity to various agents | 52.87 | 16.56 | 18 | 17202 | 177165 | 29758093 |
Drug interaction | 50.37 | 16.56 | 26 | 17194 | 199542 | 29735716 |
Nocardiosis | 48.09 | 16.56 | 28 | 17192 | 3427 | 29931831 |
Weight increased | 47.24 | 16.56 | 121 | 17099 | 74792 | 29860466 |
Thrombocytopenia | 46.97 | 16.56 | 179 | 17041 | 136865 | 29798393 |
Graft versus host disease | 46.77 | 16.56 | 42 | 17178 | 10108 | 29925150 |
Epistaxis | 45.95 | 16.56 | 97 | 17123 | 52884 | 29882374 |
Completed suicide | 45.44 | 16.56 | 3 | 17217 | 99489 | 29835769 |
Graft versus host disease in gastrointestinal tract | 43.06 | 16.56 | 25 | 17195 | 3044 | 29932214 |
Transfusion | 42.79 | 16.56 | 35 | 17185 | 7426 | 29927832 |
Leukocytosis | 42.54 | 16.56 | 57 | 17163 | 21445 | 29913813 |
Flatulence | 42.05 | 16.56 | 52 | 17168 | 18077 | 29917181 |
Blast cells present | 40.93 | 16.56 | 11 | 17209 | 161 | 29935097 |
Platelet count abnormal | 40.69 | 16.56 | 22 | 17198 | 2335 | 29932923 |
Haematocrit decreased | 40.10 | 16.56 | 67 | 17153 | 30632 | 29904626 |
Early satiety | 39.92 | 16.56 | 14 | 17206 | 515 | 29934743 |
Leukaemia | 38.84 | 16.56 | 24 | 17196 | 3273 | 29931985 |
Pneumonia | 38.44 | 16.56 | 325 | 16895 | 333981 | 29601277 |
Primary myelofibrosis | 38.10 | 16.56 | 9 | 17211 | 75 | 29935183 |
Eye infection fungal | 37.96 | 16.56 | 12 | 17208 | 318 | 29934940 |
Graft versus host disease in liver | 34.48 | 16.56 | 15 | 17205 | 987 | 29934271 |
Blast cell crisis | 32.56 | 16.56 | 8 | 17212 | 80 | 29935178 |
Overdose | 32.18 | 16.56 | 5 | 17215 | 84332 | 29850926 |
Squamous cell carcinoma | 31.51 | 16.56 | 34 | 17186 | 10216 | 29925042 |
Hypotension | 31.05 | 16.56 | 42 | 17178 | 200523 | 29734735 |
Polycythaemia vera | 29.64 | 16.56 | 9 | 17211 | 208 | 29935050 |
Thyroid gland abscess | 29.05 | 16.56 | 7 | 17213 | 64 | 29935194 |
Necrotising retinitis | 28.74 | 16.56 | 12 | 17208 | 713 | 29934545 |
Retinal ischaemia | 28.67 | 16.56 | 10 | 17210 | 362 | 29934896 |
Splenectomy | 27.72 | 16.56 | 10 | 17210 | 400 | 29934858 |
Adenovirus infection | 26.55 | 16.56 | 21 | 17199 | 4247 | 29931011 |
Infectious thyroiditis | 26.14 | 16.56 | 7 | 17213 | 101 | 29935157 |
Skin cancer | 25.51 | 16.56 | 27 | 17193 | 7934 | 29927324 |
Increased appetite | 25.40 | 16.56 | 23 | 17197 | 5594 | 29929664 |
Varicella zoster virus infection | 25.19 | 16.56 | 13 | 17207 | 1255 | 29934003 |
Haemorrhage | 24.56 | 16.56 | 70 | 17150 | 46009 | 29889249 |
Graft versus host disease in skin | 24.37 | 16.56 | 18 | 17202 | 3289 | 29931969 |
Serum ferritin increased | 24.07 | 16.56 | 22 | 17198 | 5415 | 29929843 |
Herpes zoster | 23.85 | 16.56 | 53 | 17167 | 29890 | 29905368 |
Gout | 22.88 | 16.56 | 38 | 17182 | 17277 | 29917981 |
Cardio-respiratory arrest | 22.78 | 16.56 | 3 | 17217 | 57303 | 29877955 |
White blood cell count decreased | 22.68 | 16.56 | 102 | 17118 | 83845 | 29851413 |
Product use in unapproved indication | 22.56 | 16.56 | 93 | 17127 | 73600 | 29861658 |
Spleen disorder | 22.22 | 16.56 | 11 | 17209 | 972 | 29934286 |
Haematocrit increased | 21.80 | 16.56 | 13 | 17207 | 1663 | 29933595 |
Syncope | 21.46 | 16.56 | 11 | 17209 | 84892 | 29850366 |
Therapeutic response unexpected | 21.39 | 16.56 | 26 | 17194 | 8877 | 29926381 |
Procedural pneumothorax | 21.35 | 16.56 | 5 | 17215 | 40 | 29935218 |
Plasma cell myeloma | 20.78 | 16.56 | 3 | 17217 | 53459 | 29881799 |
Splenic infarction | 20.77 | 16.56 | 13 | 17207 | 1812 | 29933446 |
Septic embolus | 20.73 | 16.56 | 11 | 17209 | 1124 | 29934134 |
Seizure | 20.44 | 16.56 | 16 | 17204 | 98459 | 29836799 |
Drug hypersensitivity | 20.33 | 16.56 | 7 | 17213 | 68512 | 29866746 |
Cerebral artery embolism | 19.99 | 16.56 | 10 | 17210 | 904 | 29934354 |
Myeloproliferative neoplasm | 19.76 | 16.56 | 8 | 17212 | 439 | 29934819 |
Cytopenia | 19.65 | 16.56 | 24 | 17196 | 8232 | 29927026 |
Scleroderma | 19.12 | 16.56 | 11 | 17209 | 1316 | 29933942 |
Graft versus host disease in lung | 18.72 | 16.56 | 8 | 17212 | 504 | 29934754 |
Haematoma | 18.63 | 16.56 | 42 | 17178 | 23911 | 29911347 |
Tuberculosis | 18.45 | 16.56 | 23 | 17197 | 8054 | 29927204 |
Red blood cell count increased | 18.36 | 16.56 | 11 | 17209 | 1418 | 29933840 |
Microangiopathy | 18.23 | 16.56 | 9 | 17211 | 791 | 29934467 |
Blood product transfusion dependent | 18.03 | 16.56 | 7 | 17213 | 344 | 29934914 |
Enterocolitis infectious | 17.64 | 16.56 | 10 | 17210 | 1164 | 29934094 |
Basophil count increased | 17.63 | 16.56 | 7 | 17213 | 365 | 29934893 |
Acute graft versus host disease in intestine | 17.52 | 16.56 | 13 | 17207 | 2392 | 29932866 |
Serum ferritin abnormal | 17.26 | 16.56 | 6 | 17214 | 215 | 29935043 |
Chronic myelomonocytic leukaemia | 16.82 | 16.56 | 8 | 17212 | 648 | 29934610 |
Bone marrow transplant | 16.61 | 16.56 | 9 | 17211 | 959 | 29934299 |
Source | Code | Description |
---|---|---|
ATC | L01EJ01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Janus-associated kinase (JAK) inhibitors |
FDA MoA | N0000175076 | Protein Kinase Inhibitors |
FDA EPC | N0000175605 | Kinase Inhibitor |
CHEBI has role | CHEBI:35610 | cytostatic |
CHEBI has role | CHEBI:76617 | abl inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Myelofibrosis | indication | 52967002 | DOID:4971 |
Polycythemia vera | indication | 109992005 | |
Myeloproliferative disorder | indication | 425333006 | |
Coronavirus infection | off-label use | 186747009 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 6.44 | acidic |
pKa2 | 4.6 | Basic |
pKa3 | 2.37 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 10MG BASE | JAKAFI | INCYTE CORP | N202192 | Nov. 16, 2011 | RX | TABLET | ORAL | Dec. 4, 2021 | TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INULLDEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA |
EQ 15MG BASE | JAKAFI | INCYTE CORP | N202192 | Nov. 16, 2011 | RX | TABLET | ORAL | Dec. 4, 2021 | TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INULLDEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA |
EQ 20MG BASE | JAKAFI | INCYTE CORP | N202192 | Nov. 16, 2011 | RX | TABLET | ORAL | Dec. 4, 2021 | TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INULLDEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA |
EQ 25MG BASE | JAKAFI | INCYTE CORP | N202192 | Nov. 16, 2011 | RX | TABLET | ORAL | Dec. 4, 2021 | TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INULLDEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA |
EQ 5MG BASE | JAKAFI | INCYTE CORP | N202192 | Nov. 16, 2011 | RX | TABLET | ORAL | Dec. 4, 2021 | TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INULLDEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA |
EQ 10MG BASE | JAKAFI | INCYTE CORP | N202192 | Nov. 16, 2011 | RX | TABLET | ORAL | May 24, 2022 | TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER |
EQ 15MG BASE | JAKAFI | INCYTE CORP | N202192 | Nov. 16, 2011 | RX | TABLET | ORAL | May 24, 2022 | TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER |
EQ 20MG BASE | JAKAFI | INCYTE CORP | N202192 | Nov. 16, 2011 | RX | TABLET | ORAL | May 24, 2022 | TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER |
EQ 25MG BASE | JAKAFI | INCYTE CORP | N202192 | Nov. 16, 2011 | RX | TABLET | ORAL | May 24, 2022 | TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER |
EQ 5MG BASE | JAKAFI | INCYTE CORP | N202192 | Nov. 16, 2011 | RX | TABLET | ORAL | May 24, 2022 | TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER |
EQ 10MG BASE | JAKAFI | INCYTE CORP | N202192 | Nov. 16, 2011 | RX | TABLET | ORAL | May 24, 2026 | TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER |
EQ 15MG BASE | JAKAFI | INCYTE CORP | N202192 | Nov. 16, 2011 | RX | TABLET | ORAL | May 24, 2026 | TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER |
EQ 20MG BASE | JAKAFI | INCYTE CORP | N202192 | Nov. 16, 2011 | RX | TABLET | ORAL | May 24, 2026 | TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER |
EQ 25MG BASE | JAKAFI | INCYTE CORP | N202192 | Nov. 16, 2011 | RX | TABLET | ORAL | May 24, 2026 | TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER |
EQ 5MG BASE | JAKAFI | INCYTE CORP | N202192 | Nov. 16, 2011 | RX | TABLET | ORAL | May 24, 2026 | TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Tyrosine-protein kinase JAK2 | Kinase | INHIBITOR | Kd | 10.44 | CHEMBL | CHEMBL | |||
Tyrosine-protein kinase JAK1 | Kinase | INHIBITOR | Ki | 10.05 | CHEMBL | CHEMBL | |||
Phosphatidylinositol 4-kinase beta | Kinase | Kd | 5.47 | CHEMBL | |||||
Serine/threonine-protein kinase DCLK1 | Kinase | Kd | 7.17 | CHEMBL | |||||
Calcium/calmodulin-dependent protein kinase type 1 | Kinase | Kd | 6.33 | CHEMBL | |||||
SRSF protein kinase 1 | Kinase | Kd | 5.68 | CHEMBL | |||||
Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Kinase | Kd | 5.43 | CHEMBL | |||||
Serine/threonine-protein kinase RIO3 | Kinase | Kd | 5.70 | CHEMBL | |||||
Serine/threonine-protein kinase Nek3 | Kinase | Kd | 5.96 | CHEMBL | |||||
Dual specificity mitogen-activated protein kinase kinase 3 | Kinase | Kd | 6.33 | CHEMBL | |||||
Calcium/calmodulin-dependent protein kinase type II subunit beta | Kinase | Kd | 6.51 | CHEMBL | |||||
Death-associated protein kinase 2 | Kinase | Kd | 7.01 | CHEMBL | |||||
Ribosomal protein S6 kinase alpha-6 | Kinase | Kd | 6.82 | CHEMBL | |||||
Ribosomal protein S6 kinase alpha-1 | Kinase | Kd | 6.92 | CHEMBL | |||||
Cyclin-G-associated kinase | Kinase | Kd | 7 | CHEMBL | |||||
Serine/threonine-protein kinase SBK1 | Kinase | Kd | 5.89 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 15 | Kinase | Kd | 5.96 | CHEMBL | |||||
Microtubule-associated serine/threonine-protein kinase 1 | Kinase | Kd | 6.28 | CHEMBL | |||||
JAK2/TYK2 | Kinase | IC50 | 6.09 | CHEMBL | |||||
JAK1/JAK2/TYK2 | Kinase | IC50 | 6.53 | CHEMBL | |||||
JAK1/TYK2 | Kinase | IC50 | 6.71 | CHEMBL | |||||
Homeodomain-interacting protein kinase 3 | Kinase | Kd | 5.92 | CHEMBL | |||||
Homeodomain-interacting protein kinase 2 | Kinase | Kd | 6 | CHEMBL | |||||
Maternal embryonic leucine zipper kinase | Kinase | Kd | 5.66 | CHEMBL | |||||
Serine/threonine-protein kinase PLK1 | Kinase | Kd | 6.89 | CHEMBL | |||||
Serine/threonine-protein kinase TBK1 | Kinase | Kd | 5.77 | CHEMBL | |||||
Serine/threonine-protein kinase Nek7 | Kinase | Kd | 5.31 | CHEMBL | |||||
Serine/threonine-protein kinase/endoribonuclease IRE1 | Kinase | Kd | 5.60 | CHEMBL | |||||
Serine/threonine-protein kinase B-raf | Kinase | Kd | 5.66 | CHEMBL | |||||
Serine/threonine-protein kinase OSR1 | Kinase | Kd | 5.57 | CHEMBL | |||||
STE20/SPS1-related proline-alanine-rich protein kinase | Kinase | Kd | 5.72 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 7 | Kinase | Kd | 6.14 | CHEMBL | |||||
Dual specificity protein kinase CLK2 | Kinase | Kd | 6.34 | CHEMBL | |||||
G protein-coupled receptor kinase 7 | Kinase | Kd | 6.27 | CHEMBL | |||||
Homeodomain-interacting protein kinase 1 | Kinase | Kd | 5.92 | CHEMBL | |||||
JAK3/JAK1 | Kinase | IC50 | 7.64 | CHEMBL | |||||
Dual specificity protein kinase TTK | Kinase | Kd | 6.32 | CHEMBL | |||||
JAK2/JAK1 | Kinase | IC50 | 7.51 | CHEMBL | |||||
Ephrin type-A receptor 3 | Kinase | Kd | 5.21 | CHEMBL | |||||
Serine/threonine-protein kinase 16 | Kinase | Kd | 6.31 | CHEMBL | |||||
Serine/threonine-protein kinase 17B | Kinase | Kd | 5.46 | CHEMBL | |||||
Calcium/calmodulin-dependent protein kinase type II subunit gamma | Kinase | Kd | 7 | CHEMBL | |||||
Serine/threonine-protein kinase PLK4 | Kinase | Kd | 6.70 | CHEMBL | |||||
AP2-associated protein kinase 1 | Kinase | Kd | 6.92 | CHEMBL | |||||
Serine/threonine-protein kinase MARK2 | Kinase | Kd | 6.18 | CHEMBL | |||||
Protein kinase C epsilon type | Kinase | Kd | 6.28 | CHEMBL | |||||
Tyrosine-protein kinase JAK3 | Kinase | Kd | 8.70 | CHEMBL | |||||
Ribosomal protein S6 kinase alpha-5 | Kinase | Kd | 6.85 | CHEMBL | |||||
Casein kinase II subunit alpha' | Kinase | Kd | 5.48 | CHEMBL | |||||
Serine/threonine-protein kinase TAO1 | Kinase | Kd | 5.89 | CHEMBL | |||||
Aurora kinase C | Kinase | Kd | 5.06 | CHEMBL | |||||
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform | Kinase | Kd | 6 | CHEMBL | |||||
High affinity nerve growth factor receptor | Kinase | Kd | 5.82 | CHEMBL | |||||
Rho-associated protein kinase 1 | Kinase | Kd | 7.22 | CHEMBL | |||||
Ankyrin repeat and protein kinase domain-containing protein 1 | Kinase | Kd | 6.41 | CHEMBL | |||||
Serine/threonine-protein kinase 25 | Kinase | Kd | 5.20 | CHEMBL | |||||
Myosin light chain kinase, smooth muscle | Kinase | Kd | 6.44 | CHEMBL | |||||
Serine/threonine-protein kinase DCLK2 | Kinase | Kd | 6.12 | CHEMBL | |||||
Leucine-rich repeat serine/threonine-protein kinase 2 | Kinase | Kd | 7.05 | CHEMBL | |||||
Serine/threonine-protein kinase PAK 6 | Kinase | Kd | 5.54 | CHEMBL | |||||
Mast/stem cell growth factor receptor Kit | Kinase | Kd | 5.20 | CHEMBL | |||||
BMP-2-inducible protein kinase | Kinase | Kd | 6.68 | CHEMBL | |||||
Serine/threonine-protein kinase PAK 7 | Kinase | Kd | 5.89 | CHEMBL | |||||
Serine/threonine-protein kinase 17A | Kinase | Kd | 5.21 | CHEMBL | |||||
Ribosomal protein S6 kinase alpha-4 | Kinase | Kd | 6.47 | CHEMBL | |||||
Dual specificity protein kinase CLK4 | Kinase | Kd | 5.77 | CHEMBL | |||||
MAP kinase-interacting serine/threonine-protein kinase 2 | Kinase | Kd | 6.70 | CHEMBL | |||||
Bone morphogenetic protein receptor type-1B | Kinase | Kd | 5.74 | CHEMBL | |||||
Non-receptor tyrosine-protein kinase TYK2 | Kinase | Ki | 9.30 | CHEMBL | |||||
Interleukin-1 receptor-associated kinase 1 | Kinase | Kd | 6.54 | CHEMBL | |||||
Calcium/calmodulin-dependent protein kinase type 1D | Kinase | Kd | 6.92 | CHEMBL | |||||
Calcium/calmodulin-dependent protein kinase type 1G | Kinase | Kd | 5.66 | CHEMBL | |||||
Inhibitor of nuclear factor kappa-B kinase subunit beta | Kinase | Kd | 5.64 | CHEMBL | |||||
Serine/threonine-protein kinase TAO2 | Kinase | Kd | 6.51 | CHEMBL | |||||
Ribosomal protein S6 kinase alpha-2 | Kinase | Kd | 6.82 | CHEMBL | |||||
Serine/threonine-protein kinase ULK2 | Kinase | Kd | 6.72 | CHEMBL | |||||
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform | Kinase | Kd | 5.24 | CHEMBL | |||||
Activated CDC42 kinase 1 | Kinase | Kd | 5.59 | CHEMBL | |||||
Casein kinase II subunit alpha | Kinase | Kd | 5.38 | CHEMBL | |||||
NT-3 growth factor receptor | Kinase | Kd | 6.48 | CHEMBL | |||||
Rhodopsin kinase | Kinase | Kd | 6.14 | CHEMBL | |||||
Calcium/calmodulin-dependent protein kinase type II subunit alpha | Kinase | Kd | 7.34 | CHEMBL | |||||
G protein-coupled receptor kinase 4 | Kinase | Kd | 5.21 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 2 | Kinase | Kd | 7.39 | CHEMBL | |||||
Serine/threonine-protein kinase ULK3 | Kinase | Kd | 5.62 | CHEMBL | |||||
Serine/threonine-protein kinase 26 | Kinase | Kd | 5.51 | CHEMBL | |||||
Serine/threonine-protein kinase PLK2 | Kinase | Kd | 5.82 | CHEMBL | |||||
Bone morphogenetic protein receptor type-2 | Kinase | Kd | 6.03 | CHEMBL | |||||
Inhibitor of nuclear factor kappa-B kinase subunit epsilon | Kinase | Kd | 5.92 | CHEMBL | |||||
Peripheral plasma membrane protein CASK | Kinase | Kd | 5.82 | CHEMBL | |||||
Ephrin type-B receptor 6 | Kinase | Kd | 5.51 | CHEMBL | |||||
Mitogen-activated protein kinase 8 | Kinase | Kd | 5.32 | CHEMBL | |||||
Serine/threonine-protein kinase TAO3 | Kinase | Kd | 6.23 | CHEMBL | |||||
Casein kinase I isoform alpha | Kinase | Kd | 5.74 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 1 | Kinase | Kd | 5.38 | CHEMBL | |||||
Cyclin-dependent kinase 7 | Kinase | Kd | 5.48 | CHEMBL | |||||
Serine/threonine-protein kinase SIK3 | Kinase | Kd | 5.89 | CHEMBL | |||||
Rho-associated protein kinase 2 | Kinase | Kd | 7.28 | CHEMBL | |||||
Death-associated protein kinase 1 | Kinase | Kd | 7.14 | CHEMBL | |||||
Uncharacterized serine/threonine-protein kinase SBK3 | Kinase | Kd | 5.24 | CHEMBL | |||||
Death-associated protein kinase 3 | Kinase | Kd | 7.05 | CHEMBL | |||||
Serine/threonine-protein kinase PAK 4 | Kinase | Kd | 5.80 | CHEMBL | |||||
Serine/threonine-protein kinase DCLK3 | Kinase | Kd | 6.59 | CHEMBL | |||||
Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Kinase | Kd | 6.04 | CHEMBL | |||||
Proto-oncogene tyrosine-protein kinase receptor Ret | Kinase | Kd | 6.72 | CHEMBL | |||||
Myotonin-protein kinase | Kinase | Kd | 5.46 | CHEMBL | |||||
Leukocyte tyrosine kinase receptor | Kinase | Kd | 6.36 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 19 | Kinase | Kd | 6.57 | CHEMBL | |||||
Serine/threonine-protein kinase PLK3 | Kinase | Kd | 6.15 | CHEMBL | |||||
BDNF/NT-3 growth factors receptor | Kinase | Kd | 6.44 | CHEMBL | |||||
NUAK family SNF1-like kinase 2 | Kinase | Kd | 6.49 | CHEMBL | |||||
Dual specificity mitogen-activated protein kinase kinase 2 | Kinase | Kd | 5.40 | CHEMBL | |||||
Dual specificity mitogen-activated protein kinase kinase 4 | Kinase | Kd | 5.74 | CHEMBL | |||||
SRSF protein kinase 3 | Kinase | Kd | 5.48 | CHEMBL | |||||
Serine/threonine-protein kinase VRK2 | Kinase | Kd | 5.40 | CHEMBL | |||||
ALK tyrosine kinase receptor | Kinase | Kd | 5.82 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 3 | Kinase | Kd | 6.82 | CHEMBL | |||||
Serine/threonine-protein kinase RIO1 | Kinase | Kd | 5.60 | CHEMBL | |||||
Serine/threonine-protein kinase RIO2 | Kinase | Kd | 5.92 | CHEMBL | |||||
Serine/threonine-protein kinase ULK1 | Kinase | Kd | 6.52 | CHEMBL | |||||
Calcium/calmodulin-dependent protein kinase type II subunit delta | Kinase | Kd | 7.05 | CHEMBL | |||||
cGMP-dependent protein kinase 2 | Kinase | Kd | 6.16 | CHEMBL | |||||
Receptor-interacting serine/threonine-protein kinase 4 | Kinase | Kd | 5.68 | CHEMBL | |||||
Dual specificity mitogen-activated protein kinase kinase 1 | Kinase | Kd | 5.72 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase kinase 2 | Kinase | Kd | 5.70 | CHEMBL | |||||
Tyrosine-protein kinase ABL1 | Kinase | Kd | 5.96 | CHEMBL | |||||
Serine/threonine-protein kinase PknB | Kinase | Kd | 5.38 | CHEMBL |
ID | Source |
---|---|
4031235 | VUID |
N0000184017 | NUI |
D09959 | KEGG_DRUG |
1092939-17-7 | SECONDARY_CAS_RN |
4031235 | VANDF |
C3247913 | UMLSCUI |
CHEBI:66917 | CHEBI |
RXT | PDB_CHEM_ID |
CHEMBL1795071 | ChEMBL_ID |
CHEMBL1789941 | ChEMBL_ID |
5688 | IUPHAR_LIGAND_ID |
C540383 | MESH_SUPPLEMENTAL_RECORD_UI |
9287 | INN_ID |
DB08877 | DRUGBANK_ID |
82S8X8XX8H | UNII |
25126798 | PUBCHEM_CID |
1193325 | RXNORM |
186162 | MMSL |
28206 | MMSL |
d07812 | MMSL |
014040 | NDDF |
014041 | NDDF |
702806008 | SNOMEDCT_US |
703779004 | SNOMEDCT_US |
734494005 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
JAKAFI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50881-005 | TABLET | 5 mg | ORAL | NDA | 28 sections |
JAKAFI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50881-010 | TABLET | 10 mg | ORAL | NDA | 28 sections |
JAKAFI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50881-015 | TABLET | 15 mg | ORAL | NDA | 28 sections |
JAKAFI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50881-020 | TABLET | 20 mg | ORAL | NDA | 28 sections |
JAKAFI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50881-025 | TABLET | 25 mg | ORAL | NDA | 28 sections |